Ecnoglutide Shows Greater Weight Loss Than Semaglutide in Trial
Ecnoglutide shows greater weight loss than semaglutide in interim trial data, with 12.8% versus 9.5% mean body weight reduction...
Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction
Survodutide Phase III trial achieves 34% visceral fat and 63% liver fat reduction, positioning the dual agonist as a...
CagriSema beats semaglutide on weight loss, HbA1c in type 2 diabetes trials
CagriSema beats semaglutide on weight loss and HbA1c reduction in type 2 diabetes trials, delivering 4-percentage-point greater weight loss...
Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal
Roche commits $2.3B to co-develop BTK degrader bexobrutideg with Nurix, targeting CLL patients resistant to conventional BTK inhibitors.
Amphista’s AMX-883 BRD9 degrader wins FDA IND clearance for AML
Amphista's AMX-883 BRD9 degrader wins FDA IND clearance for AML, with Phase 1 trials opening in late 2026 targeting...
Cloudbreak Pharma Completes Phase 3 Enrollment for Pterygium Eye Drop CBT-001
Cloudbreak Pharma completes Phase 3 enrollment for CBT-001 eye drop targeting pterygium. Topline data expected Q3 2026 across 660...
Petrelintide achieves 10.7% weight loss with 1.5% GI discontinuation rate in Phase 2
Petrelintide weight loss reaches 10.7% in Phase 2 with only 1.5% GI discontinuation rate, advancing toward Phase 3 trials...
Regeneron Presents Phase 3 Garetosmab Data for Fibrodysplasia Ossificans Progressiva
Regeneron presents Phase 3 garetosmab data for fibrodysplasia ossificans progressiva at ENDO while FDA Priority Review proceeds on the...
Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial
Retatrutide achieves 28.3% weight loss in Phase 3 obesity trial, significantly exceeding results from competing GLP-1 receptor agonists over...
Climb Bio’s CLYM116 Shows Clean Phase 1 Safety in IgAN Program
CLYM116 Phase 1 safety data shows all adverse events were Grade 1–2 and self-resolving in healthy volunteers dosed up...